In vivo effects of indomethacin and cyclophosphamide on CFU-GM proliferation and cyclic nucleotide levels in bone marrow of mice.
The effects of indomethacin (6 mg/kg daily, orally, for 4 days) or cyclophosphamide (150 mg/kg, a single dose, intraperitoneally) on myelopoiesis were studied in mice. A hyperplasia of the committed stem cell compartment (rise in the recognizable myeloid precursors, increase of both colony forming capacity and number of CFU-GM in S-phase) associated to an increase of cyclic AMP and GMP amounts in bone marrow cells of treated mice were observed. These results suggest a possible relationship between the in vitro enhancement of proliferative activity of CFU-GM and the in vivo increase of both cyclic nucleotide levels in medullary environment.
D000818:Animals; D001853:Bone Marrow / Q000187:drug effects* / Q000378:metabolism; D001854:Bone Marrow Cells; D002455:Cell Division / Q000187:drug effects; D003115:Colony-Stimulating Factors / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism*; D006152:Cyclic GMP / Q000378:metabolism*; D003520:Cyclophosphamide / Q000494:pharmacology*; D006098:Granulocytes / Q000187:drug effects; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D007213:Indomethacin / Q000494:pharmacology*; D008264:Macrophages / Q000187:drug effects; D008297:Male; D051379:Mice; D011453:Prostaglandins / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism
D003115:Colony-Stimulating Factors; D011453:Prostaglandins; D003520:Cyclophosphamide; D000242:Cyclic AMP; D006152:Cyclic GMP; D013936:Thymidine; D007213:Indomethacin